https://www.pharmaradar360.com/article/3139ffeba101896bPharma Surgeen2026-08-06T10:20:44.000ZΣύσκεψη στον ΕΟΦ για την ομαλή λειτουργία της εφοδιαστικής αλυσίδας των φαρμάκων.https://www.pharmaradar360.com/article/mergers-as-strategic-architecture-rethinking-how-to-evaluate-the-astrazeneca-bms-5e14674f98cdcbb8Pharma Surgeen2026-08-06T10:02:44.000ZMergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumorshttps://www.pharmaradar360.com/article/context-scraps-bispecific-t-cell-engager-program-to-extend-cash-runway-deeper-in-3cee9dbd62b9c864Pharma Surgeen2026-08-06T09:55:15.000ZContext scraps bispecific T-cell engager program to extend cash runway deeper into 2027https://www.pharmaradar360.com/article/onconic-s-gerd-drug-jaqbo-wins-first-overseas-approval-in-india-57405c4ad7e906ffPharma Surgeen2026-08-06T09:34:40.000ZOnconic’s GERD drug Jaqbo wins first overseas approval in Indiahttps://www.pharmaradar360.com/article/a1adfbf3ea7345cfPharma Surgeen2026-08-06T09:32:32.000ZΦαρμακευτικά προϊόντα που περιέχουν δεσογεστρέλη και ετονογεστρέλη: Απευθείας επικοινωνία προς επαγγελματίες υγείαςhttps://www.pharmaradar360.com/article/why-global-pharmaceutical-reforms-are-quietly-redirecting-rare-disease-innovatio-b876733305dfdef2Pharma Surgeen2026-08-06T09:30:00.000ZWhy global pharmaceutical reforms are quietly redirecting rare disease innovationhttps://www.pharmaradar360.com/article/al-biotech-facility-focused-on-rare-diseases-to-close-lay-off-47-858eed896fbf7c36Pharma Surgeen2026-08-06T09:10:00.000ZAL biotech facility focused on rare diseases to close, lay off 47https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-08-06T09:03:18.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/registration-procedure-for-veterinary-medicinal-products-with-a-centralised-mark-9b89e709f65a2fa4Pharma Surgeen2026-08-06T08:56:56.000ZREGISTRATION PROCEDURE FOR VETERINARY MEDICINAL PRODUCTS WITH A CENTRALISED MARKETING AUTHORISATIONhttps://www.pharmaradar360.com/article/ec6667ff9bc032f9Pharma Surgeen2026-08-06T08:55:10.000ZΔΙΑΔΙΚΑΣΙΑ ΚΑΤΑΧΩΡΙΣΗΣ ΚΤΗΝΙΑΤΡΙΚΩΝ ΦΑΡΜΑΚΩΝ ΜΕ ΚΕΝΤΡΙΚΗ ΑΔΕΙΑ ΚΥΚΛΟΦΟΡΙΑΣhttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-bvs-tvtx-odtx-crl-climb-with-q2-results-acrs-b63f63ee43cb1eaePharma Surgeen2026-08-06T08:54:00.000ZBiotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRShttps://www.pharmaradar360.com/article/registration-and-variation-procedure-for-veterinary-medicinal-products-with-a-ce-b476233a56c133bePharma Surgeen2026-08-06T08:51:48.000ZREGISTRATION AND VARIATION PROCEDURE FOR VETERINARY MEDICINAL PRODUCTS WITH A CENTRALISED MARKETING AUTHORISATION (MA)https://www.pharmaradar360.com/article/c523a00ad59cea38Pharma Surgeen2026-08-06T08:30:48.000ZΔΙΑΔΙΚΑΣΙΑ ΚΑΤΑΧΩΡΙΣΗΣ ΚΑΙ ΤΡΟΠΟΠΟΙΗΣΗΣ ΚΤΗΝΙΑΤΡΙΚΩΝ ΦΑΡΜΑΚΩΝ ΜΕ ΚΕΝΤΡΙΚΗ ΑΔΕΙΑ ΚΥΚΛΟΦΟΡΙΑΣ (Α.Κ.)https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-08-06T08:30:05.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884Pharma Surgeen2026-08-06T08:30:04.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-b306771583db51dfPharma Surgeen2026-08-06T08:30:02.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in Englandhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-e72ee03f6bc9d959Pharma Surgeen2026-08-06T08:30:02.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in Englandhttps://www.pharmaradar360.com/article/cosmogen-asquan-equip-biotech-beauty-brand-with-refill-sun-care-stick-f95ace39d14093cbPharma Surgeen2026-08-06T08:26:37.000ZCosmogen & Asquan equip biotech beauty brand with refill sun care stickhttps://www.pharmaradar360.com/article/portable-gas-detection-in-the-pharmaceutical-sector-016ce0e5916d168dPharma Surgeen2026-08-06T07:59:48.000ZPortable gas detection in the pharmaceutical sectorhttps://www.pharmaradar360.com/article/cumberland-pharmaceuticals-cpix-stock-cools-as-cash-rich-biotech-pivot-begins-d504ed124069cca3Pharma Surgeen2026-08-06T07:40:40.000ZCumberland Pharmaceuticals (CPIX) Stock Cools As Cash Rich Biotech Pivot Beginshttps://www.pharmaradar360.com/article/table-fuji-pharmaceutical-9-mth-group-results-3f4f507a7929b2ccPharma Surgeen2026-08-06T07:30:20.000ZTABLE-Fuji Pharmaceutical - 9-MTH group resultshttps://www.pharmaradar360.com/article/this-simple-tool-may-bring-caries-to-a-halt-50c0601a5220edd3Pharma Surgeen2026-08-06T07:30:00.000ZThis simple tool may bring caries to a halthttps://www.pharmaradar360.com/article/promising-treatments-for-aggressive-cancer-emerge-from-phase-3-trial-c6d0f4fb6392519ePharma Surgeen2026-08-06T07:21:20.000ZPromising treatments for aggressive cancer emerge from phase 3 trialhttps://www.pharmaradar360.com/article/k-pharma-expands-push-into-latin-america-c6659e7c10c2b2aaPharma Surgeen2026-08-06T07:20:16.000ZK-Pharma Expands Push Into Latin Americahttps://www.pharmaradar360.com/article/guidance-clinical-investigations-compiling-a-submission-c9d6540f2d54d8cdPharma Surgeen2026-08-06T07:16:12.000ZGuidance: Clinical investigations: compiling a submissionhttps://www.pharmaradar360.com/article/ultragenyx-rare-stock-revenue-record-clashes-with-ongoing-cash-burn-bf90e5c9f9c8e78aPharma Surgeen2026-08-06T07:06:23.000ZUltragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burnhttps://www.pharmaradar360.com/article/model-van-diergeneeskundig-voorschrift-nieuwe-verplichte-vermeldingen-6f913646dc142d52Pharma Surgeen2026-08-06T07:05:54.000ZModel van diergeneeskundig voorschrift: nieuwe verplichte vermeldingenhttps://www.pharmaradar360.com/article/cros-vs-biotechs-finding-the-right-fit-20569bf843b94165Pharma Surgeen2026-08-06T07:02:54.000ZCROs vs. biotechs: Finding the right fithttps://www.pharmaradar360.com/article/could-helus-pharma-s-new-ceo-reframe-cybin-s-help-path-from-clinical-trials-to-c-9cd80a1d808149f6Pharma Surgeen2026-08-06T06:49:30.000ZCould Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?https://www.pharmaradar360.com/article/maharashtra-fda-to-fast-track-restoration-of-suspended-food-business-licences-tu-c1236f1370ce02daPharma Surgeen2026-08-06T06:12:00.000ZMaharashtra FDA to fast-track restoration of suspended food business licences: Tukaram Mundhehttps://www.pharmaradar360.com/article/south-korean-firm-develops-human-fat-skin-booster-to-treat-ozempic-face-594fe32a637258b2Pharma Surgeen2026-08-06T04:25:26.000ZSouth Korean firm develops human fat skin booster to treat ‘Ozempic face’https://www.pharmaradar360.com/article/how-emerging-biotech-companies-should-choose-a-cro-partner-061bfc4be3818771Pharma Surgeen2026-08-06T03:19:10.000ZHow Emerging Biotech Companies Should Choose a CRO Partnerhttps://www.pharmaradar360.com/article/child-died-in-chinese-biotech-firm-s-gene-editing-trial-e83ecb7856e6e4b0Pharma Surgeen2026-08-06T03:00:00.000ZChild Died in Chinese Biotech Firm’s Gene Editing Trialhttps://www.pharmaradar360.com/article/synthekine-appoints-veteran-biotech-leader-susan-m-molineaux-ph-d-as-chief-execu-a69e56e7529a33bcPharma Surgeen2026-08-06T02:42:34.000ZSynthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officerhttps://www.pharmaradar360.com/article/blackrock-inc-buys-ultragenyx-pharmaceutical-inc-rare-sha-544560eae2eeca47Pharma Surgeen2026-08-06T02:37:30.000ZBlackRock, Inc. Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shahttps://www.pharmaradar360.com/article/deepnoid-s-remote-reading-platform-axonflow-wins-south-korean-fda-approval-expan-8a790d5a0145c8ffPharma Surgeen2026-08-06T02:06:00.000ZDeepnoid's Remote Reading Platform 'AxonFlow' Wins South Korean FDA Approval, Expanding Medical AI Serviceshttps://www.pharmaradar360.com/article/prioritisation-activity-in-the-june-quarter-6cdb0633209e2f46Pharma Surgeen2026-08-06T02:00:00.000ZPrioritisation activity in the June quarterhttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-next-generation-enzymatic-dna-synthesis-advanced-nucleases-e7773c88b4c1b53ePharma Surgeen2026-08-06T01:30:29.000ZThe biotech bi-weekly: next-generation enzymatic DNA synthesis, advanced nucleases and AI-driven biologics drug discoveryhttps://www.pharmaradar360.com/article/onconic-wins-india-approval-for-ja-q-bo-accelerates-global-commercialization-cho-1176ddee992a5516Pharma Surgeen2026-08-06T01:25:00.000ZOnconic wins India approval for Ja Q Bo, accelerates global commercialization - CHOSUNBIZhttps://www.pharmaradar360.com/article/innovent-announces-first-patient-dosed-in-pivotal-registrational-study-of-ibi363-4f9199d857eb6df2Pharma Surgeen2026-08-06T00:33:27.000ZInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in Chinahttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-68726f95fc90c031Pharma Surgeen2026-08-06T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-032db2a0c1ddaf39Pharma Surgeen2026-08-06T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-30a50cbd2e9a1c2ePharma Surgeen2026-08-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-c05a8617653ff9e7Pharma Surgeen2026-08-06T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-36bd3996ef569320Pharma Surgeen2026-08-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a3ce923b37aea348Pharma Surgeen2026-08-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-6c8f654e08f19173Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-58c893ab540633e5Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4f7b900550cd74c8Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-91ceaee1052c3634Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-92e4f339e8e57e86Pharma Surgeen2026-08-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5c2bd1ffe95c7d66Pharma Surgeen2026-08-06T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-7d0d3ea8c622f9d2Pharma Surgeen2026-08-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-a584b34e56fb5d44Pharma Surgeen2026-08-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-c3e1aaf154b9e213Pharma Surgeen2026-08-06T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/data-monitoring-committees-in-chinese-clinical-trials-institutional-empowerment-2bc887cbc412b0c4Pharma Surgeen2026-08-06T00:00:00.000ZData Monitoring Committees in Chinese Clinical Trials: Institutional Empowerment and the New Landscape of Global Pharmaceutical Innovationhttps://www.pharmaradar360.com/article/the-role-of-a-specialized-hospital-in-the-treatment-of-testicular-germ-cell-tumo-5fff4e142a94cc14Pharma Surgeen2026-08-06T00:00:00.000ZThe role of a specialized hospital in the treatment of testicular germ cell tumors (literature review, case studies)https://www.pharmaradar360.com/article/use-of-balloon-tamponade-device-for-aortoesophageal-fistula-a-case-report-aab463a83a494880Pharma Surgeen2026-08-06T00:00:00.000ZUse of Balloon Tamponade Device for Aortoesophageal Fistula: A Case Reporthttps://www.pharmaradar360.com/article/berberine-poisoning-with-polymorphic-ventricular-tachycardia-a-case-report-417013ff65709cbcPharma Surgeen2026-08-06T00:00:00.000ZBerberine Poisoning with Polymorphic Ventricular Tachycardia: A Case Reporthttps://www.pharmaradar360.com/article/influence-of-clinical-and-demographic-factors-on-the-two-year-results-of-arthrom-bb7dbe7f6ea321c0Pharma Surgeen2026-08-06T00:00:00.000ZInfluence of clinical and demographic factors on the two-year results of arthromedullar bypass in gonarthrosishttps://www.pharmaradar360.com/article/incidence-profile-of-side-effects-of-anti-tuberculosis-drugs-and-adherence-to-ta-f260228d7c4bf5e4Pharma Surgeen2026-08-06T00:00:00.000ZIncidence Profile of Side Effects of Anti-Tuberculosis Drugs and Adherence To Taking Medication In Tuberculosis Patients At The Sukolilo 1 Health Centerhttps://www.pharmaradar360.com/article/schwannoma-of-the-submandibular-gland-in-a-16-year-old-patient-a-clinical-case-r-27b236b465f6d243Pharma Surgeen2026-08-06T00:00:00.000ZSchwannoma of the submandibular gland in a 16-year-old patient: a clinical case repor thttps://www.pharmaradar360.com/article/micronutrients-in-pediatric-asthma-biological-mechanisms-and-clinical-evidence-a-19060791bafb3673Pharma Surgeen2026-08-06T00:00:00.000ZMicronutrients in Pediatric Asthma: Biological Mechanisms and Clinical Evidence—A Narrative Reviewhttps://www.pharmaradar360.com/article/clinical-impact-of-multidrug-resistant-bacterial-infections-in-critically-ill-pa-5450516556c2c575Pharma Surgeen2026-08-06T00:00:00.000ZClinical Impact of Multidrug-Resistant Bacterial Infections in Critically Ill Patients: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/imaging-based-markers-of-sarcopenia-in-lower-limb-ischemia-a-systematic-review-f066e8ec8a852b4cPharma Surgeen2026-08-06T00:00:00.000ZImaging-Based Markers of Sarcopenia in Lower Limb Ischemia: A Systematic Reviewhttps://www.pharmaradar360.com/article/diabetic-retinopathy-grading-and-concurrent-cardiorenal-biomarker-abnormalities-9723d5ad4177097ePharma Surgeen2026-08-06T00:00:00.000ZDiabetic Retinopathy Grading and Concurrent Cardiorenal Biomarker Abnormalities in Type 2 Diabetes: Albuminuria and Elevated NT-proBNP—A Retrospective Cross-Sectional Studyhttps://www.pharmaradar360.com/article/a-pilot-study-of-helicopter-emergency-medical-services-in-the-zhoushan-archipela-40fb5e93fff72314Pharma Surgeen2026-08-06T00:00:00.000ZA pilot study of helicopter emergency medical services in the Zhoushan Archipelago: clinical experience and operational insights from 18 caseshttps://www.pharmaradar360.com/article/participant-food-tracking-in-psychiatric-ketogenic-metabolic-therapy-an-unresolv-60ecff2d38798bc3Pharma Surgeen2026-08-06T00:00:00.000ZParticipant food tracking in psychiatric ketogenic metabolic therapy: an unresolved clinical, psychosocial, and implementation questionhttps://www.pharmaradar360.com/article/vitamin-b6-in-nausea-and-vomiting-of-pregnancy-metabolism-mechanisms-and-clinica-73c6ff3054a62547Pharma Surgeen2026-08-06T00:00:00.000ZVitamin B6 in nausea and vomiting of pregnancy: metabolism, mechanisms, and clinical implications—a narrative reviewhttps://www.pharmaradar360.com/article/clinical-characteristics-and-diagnostic-challenges-of-non-st-segment-elevation-a-e2009983645eb72cPharma Surgeen2026-08-06T00:00:00.000ZClinical characteristics and diagnostic challenges of non-ST-segment elevation acute coronary syndrome patients with normal electrocardiograms: a reviewhttps://www.pharmaradar360.com/article/demographic-and-clinical-characteristics-of-brachial-plexus-injury-at-kirtipur-h-5bdebebfa0ed85cdPharma Surgeen2026-08-06T00:00:00.000ZDemographic and Clinical Characteristics of Brachial Plexus Injury at Kirtipur Hospitalhttps://www.pharmaradar360.com/article/the-role-of-social-media-in-shaping-political-ideology-in-rural-india-7ac1621de271df21Pharma Surgeen2026-08-06T00:00:00.000ZTHE ROLE OF SOCIAL MEDIA IN SHAPING POLITICAL IDEOLOGY IN RURAL INDIAhttps://www.pharmaradar360.com/article/cardiovascular-morbidity-and-dyslipidaemia-across-the-spectrum-of-hypothyroidism-c935166a60c8a89dPharma Surgeen2026-08-06T00:00:00.000ZCardiovascular Morbidity and Dyslipidaemia Across the Spectrum of Hypothyroidism: A Cross-Sectional Study from a Tertiary Care Centre in Southern Indiahttps://www.pharmaradar360.com/article/psychological-well-being-occupational-stress-and-resilience-among-ambulance-driv-9c054c681b930fd6Pharma Surgeen2026-08-06T00:00:00.000ZPsychological Well-Being, Occupational Stress and Resilience among Ambulance Drivers in Emergency Medical Serviceshttps://www.pharmaradar360.com/article/development-of-a-topical-gel-containing-5-fluorouracil-loaded-microsponges-for-s-f54ea3d3dff1f828Pharma Surgeen2026-08-06T00:00:00.000ZDevelopment of a Topical Gel Containing 5-Fluorouracil-Loaded Microsponges for Sustained Drug Deliveryhttps://www.pharmaradar360.com/article/laser-versus-ultrasound-at-acupuncture-points-on-chronic-non-specific-low-back-p-3fa30aad3a264c08Pharma Surgeen2026-08-06T00:00:00.000ZLaser Versus Ultrasound at Acupuncture Points on Chronic Non-Specific Low Back Painhttps://www.pharmaradar360.com/article/development-and-in-vivo-characterization-of-calcipotriol-niosomal-gel-for-psoria-db6924ca2fc59430Pharma Surgeen2026-08-06T00:00:00.000ZDevelopment and In Vivo Characterization of Calcipotriol Niosomal Gel for Psoriasis Managementhttps://www.pharmaradar360.com/article/polyherbal-fruit-peel-formulation-of-annona-squamosa-malus-domestica-psidium-gua-88a35cee1e8ed422Pharma Surgeen2026-08-06T00:00:00.000ZPolyherbal Fruit Peel Formulation of Annona squamosa, Malus domestica, Psidium guajava, and Punica granatum Attenuates Diabetic Neuropathy in Streptozotocin-Induced Rats.https://www.pharmaradar360.com/article/infant-feeding-practices-among-the-oraon-tribal-mothers-in-sundargarh-district-o-d55d4e46a02f808fPharma Surgeen2026-08-06T00:00:00.000ZInfant Feeding Practices among the Oraon Tribal Mothers in Sundargarh District of Odishahttps://www.pharmaradar360.com/article/deciphering-the-biophysical-properties-of-a-novel-linear-conotoxin-recombinant-e-a11b827cdc436a69Pharma Surgeen2026-08-06T00:00:00.000ZDeciphering the Biophysical Properties of a Novel Linear Conotoxin: Recombinant Expression and Profiling of Mo1692https://www.pharmaradar360.com/article/a-study-to-assess-the-level-of-perfectionism-and-health-status-among-undergradua-520c4187d5af8e78Pharma Surgeen2026-08-06T00:00:00.000ZA study to assess the level of perfectionism and health status among undergraduates of a selected College of Nursing, Ludhiana, Punjabhttps://www.pharmaradar360.com/article/proton-coupled-alternating-access-in-a-versatile-mycobacterial-spns-drug-transpo-a33b51a401e0e11aPharma Surgeen2026-08-06T00:00:00.000ZProton-coupled alternating access in a versatile mycobacterial Spns drug transporterhttps://www.pharmaradar360.com/article/structural-decoupling-index-based-characterization-of-hierarchical-brain-structu-0783aad759510f06Pharma Surgeen2026-08-06T00:00:00.000ZStructural decoupling index–based characterization of hierarchical brain structure–function coupling alterations and their clinical and molecular associations in migraine: a cross-sectional studyhttps://www.pharmaradar360.com/article/chemotherapy-response-score-as-a-surrogate-endpoint-for-clinical-efficacy-of-neo-6d802be4e8f42c17Pharma Surgeen2026-08-06T00:00:00.000ZChemotherapy Response Score as a surrogate endpoint for clinical efficacy of neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high grade serous ovarian cancer (iPRIME): A randomized, non-comparative phase 2 clinical trialhttps://www.pharmaradar360.com/article/integrated-clinical-environmental-and-healthcare-worker-hand-surveillance-for-un-edfb021d374f4664Pharma Surgeen2026-08-06T00:00:00.000ZIntegrated clinical, environmental, and healthcare-worker hand surveillance for unit-level infection prevention prioritisation in a Mongolian tertiary hospital: a two-component observational studyhttps://www.pharmaradar360.com/article/effect-of-plasma-rich-in-growth-factor-with-bridge-flap-in-management-of-miller-d44dfdecf11df131Pharma Surgeen2026-08-06T00:00:00.000ZEffect of Plasma rich in growth factor with bridge flap in management of Miller’s class I and II gingival recession defects: a comparative clinical studyhttps://www.pharmaradar360.com/article/sharing-tales-that-teach-protocol-for-a-cohort-embedded-randomised-trial-of-care-d97e6a8a49e07643Pharma Surgeen2026-08-06T00:00:00.000ZSharing Tales That Teach: Protocol for a cohort-embedded randomised trial of caregiver-delivered emotion-focused shared reading in young childrenhttps://www.pharmaradar360.com/article/a-phase-ii-trial-of-adi-peg20-in-combination-with-gemcitabine-and-docetaxel-for-5a03ec04a05c4090Pharma Surgeen2026-08-06T00:00:00.000ZA Phase II Trial of ADI-PEG20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcomahttps://www.pharmaradar360.com/article/clinical-case-of-repeated-pregnancy-during-the-menstrual-cycle-following-medicat-ab52ff1e93896ae1Pharma Surgeen2026-08-06T00:00:00.000ZClinical case of repeated pregnancy during the menstrual cycle following medication abortion.https://www.pharmaradar360.com/article/salivary-thioredoxin-1-as-a-non-invasive-redox-biomarker-in-oral-diseases-84492672d18a72d6Pharma Surgeen2026-08-06T00:00:00.000ZSalivary thioredoxin-1 as a non-invasive redox biomarker in oral diseaseshttps://www.pharmaradar360.com/article/monostotic-chronic-nonbacterial-osteomyelitis-chronic-recurrent-multifocal-osteo-5cd09a887570ef0aPharma Surgeen2026-08-06T00:00:00.000ZMonostotic chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis of clavicle mimicking malignant bone tumor: A case report and review of literaturehttps://www.pharmaradar360.com/article/irritable-bowel-syndrome-and-colon-cancer-a-meta-analysis-ed1d6ea487d76d8ePharma Surgeen2026-08-06T00:00:00.000ZIrritable bowel syndrome and colon cancer: A meta-analysishttps://www.pharmaradar360.com/article/laparoscopic-repair-of-a-rare-morgagni-hernia-a-case-report-af3ce262350005b7Pharma Surgeen2026-08-06T00:00:00.000ZLaparoscopic repair of a rare Morgagni hernia: A case reporthttps://www.pharmaradar360.com/article/the-therapeutic-landscape-of-cannabidiol-a-systematic-review-of-molecular-mechan-ef13709a479c81d7Pharma Surgeen2026-08-06T00:00:00.000ZThe therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changeshttps://www.pharmaradar360.com/article/correction-18f-fdg-pet-ct-performs-better-than-ct-in-determining-the-bone-biopsy-bb5ea796f4ee2dd0Pharma Surgeen2026-08-06T00:00:00.000ZCorrection: [18F]FDG PET/CT performs better than CT in determining the bone biopsy site : randomized controlled clinical trialhttps://www.pharmaradar360.com/article/predictors-of-target-lesion-failure-in-patients-with-in-stent-restenosis-insight-387ab2ecbb6f01f1Pharma Surgeen2026-08-06T00:00:00.000ZPredictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trialhttps://www.pharmaradar360.com/article/phylogenetic-diversity-of-pseudomonas-aeruginosa-from-diverse-clinical-infection-ea86ab55a57bb231Pharma Surgeen2026-08-06T00:00:00.000ZPhylogenetic Diversity of Pseudomonas aeruginosa from Diverse Clinical Infections Based on 16S rRNA Gene Sequence Analysishttps://www.pharmaradar360.com/article/associations-between-antiparietal-cell-antibody-values-and-atrophy-in-a-south-an-870118e7770efd06Pharma Surgeen2026-08-06T00:00:00.000ZAssociations Between Antiparietal Cell Antibody Values and Atrophy in a South and Southeast Asian General Populationhttps://www.pharmaradar360.com/article/the-role-of-artificial-intelligence-combined-with-digital-cholangioscopy-for-ind-d6c2abe6024dfcdbPharma Surgeen2026-08-06T00:00:00.000ZThe Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictureshttps://www.pharmaradar360.com/article/two-new-stroke-clinical-trials-evaluate-worth-of-combination-therapies-b423bb36cd6e4abbPharma Surgeen2026-08-06T00:00:00.000ZTwo New Stroke Clinical Trials Evaluate Worth of Combination Therapieshttps://www.pharmaradar360.com/article/conservative-oxygen-for-unresponsive-patients-after-cardiac-arrest-2e31edc2dc9e00e8Pharma Surgeen2026-08-06T00:00:00.000ZConservative Oxygen for Unresponsive Patients after Cardiac Arresthttps://www.pharmaradar360.com/article/clinical-characteristics-of-patients-infected-with-bundibugyo-virus-drc-2026-28e3f76d2672ff2dPharma Surgeen2026-08-06T00:00:00.000ZClinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026https://www.pharmaradar360.com/article/clinical-and-radiographic-evaluation-of-natural-bovine-bone-with-hyaluronic-acid-a6f733b774ce64e2Pharma Surgeen2026-08-06T00:00:00.000ZClinical and radiographic evaluation of natural bovine bone with hyaluronic acid on osseointegration of immediate implants: a randomized clinical studyhttps://www.pharmaradar360.com/article/a-suite-of-engineered-mice-for-interrogating-psychedelic-drug-actions-649c4a7e0cb40078Pharma Surgeen2026-08-06T00:00:00.000ZA suite of engineered mice for interrogating psychedelic drug actionshttps://www.pharmaradar360.com/article/clinical-outcomes-following-insertion-of-second-generation-aspira-tunneled-indwe-88478d215089816ePharma Surgeen2026-08-06T00:00:00.000ZClinical outcomes following insertion of second-generation (Aspira®) tunneled indwelling peritoneal catheters to treat malignant asciteshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-high-dose-retatrutide-in-adults-with-obesity-and-type-2-d-6f92c9571c290734Pharma Surgeen2026-08-06T00:00:00.000ZEfficacy and Safety of High-Dose Retatrutide in Adults with Obesity and Type 2 Diabetes: A Systematic Review and Bayesian Meta-Analysishttps://www.pharmaradar360.com/article/undertriage-of-geriatric-trauma-patients-in-the-emergency-department-a-retrospec-f3037345923e5510Pharma Surgeen2026-08-06T00:00:00.000ZUndertriage of geriatric trauma patients in the emergency department: A retrospective single-center studyhttps://www.pharmaradar360.com/article/clinical-research-on-microecological-landscape-for-infection-risk-stratification-faa15ecc26ba4dc3Pharma Surgeen2026-08-06T00:00:00.000ZClinical Research on Microecological Landscape for Infection Risk Stratification in Newly Diagnosed Patients with Hematological Conditionshttps://www.pharmaradar360.com/article/molecular-diagnostics-as-the-clinical-standard-in-cholangiocarcinoma-and-hepatoc-e7ff41e9ed3bbe3fPharma Surgeen2026-08-06T00:00:00.000ZMolecular diagnostics as the clinical standard in cholangiocarcinoma and hepatocellular carcinoma: a new era of precision oncologyhttps://www.pharmaradar360.com/article/antimicrobial-antibiofilm-and-virulence-gene-modulatory-effects-of-supercritical-06ba5c12a9fb97baPharma Surgeen2026-08-06T00:00:00.000ZAntimicrobial, antibiofilm, and virulence gene modulatory effects of supercritical CO₂ extracts of Thymbra spicata against clinical MRSA isolateshttps://www.pharmaradar360.com/article/renal-safety-of-amikacin-compared-with-ceftriaxone-in-patients-treated-for-urina-465d70b3d28ff294Pharma Surgeen2026-08-06T00:00:00.000ZRenal safety of amikacin compared with ceftriaxone in patients treated for urinary tract infection: an observational cohort studyhttps://www.pharmaradar360.com/article/improving-self-efficacy-through-nurse-navigation-in-patients-during-treatment-fo-a5df8b5657fef8a1Pharma Surgeen2026-08-06T00:00:00.000ZImproving self-efficacy through nurse navigation in patients during treatment for colorectal cancer: a randomized controlled trialhttps://www.pharmaradar360.com/article/modified-sutureless-flanged-intrascleral-intraocular-lens-fixation-in-pediatric-d5c4b86ba1750120Pharma Surgeen2026-08-06T00:00:00.000ZModified sutureless flanged intrascleral intraocular lens fixation in pediatric patients: clinical outcomes over 2 years of follow-uphttps://www.pharmaradar360.com/article/efficacy-and-safety-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-ps-e77bf9fe39edfa4bPharma Surgeen2026-08-06T00:00:00.000ZEfficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trialhttps://www.pharmaradar360.com/article/association-and-discriminative-value-of-serum-inflammatory-biomarkers-for-sarcop-e0267c40f91e2c53Pharma Surgeen2026-08-06T00:00:00.000ZAssociation and discriminative value of serum inflammatory biomarkers for sarcopenic obesity: A retrospective cross‐sectional studyhttps://www.pharmaradar360.com/article/3-healthcare-stocks-retail-investors-are-watching-as-hiring-slows-7ac4a278f8d5d47fPharma Surgeen2026-08-05T23:41:18.000Z3 Healthcare Stocks Retail Investors Are Watching As Hiring Slowshttps://www.pharmaradar360.com/article/us-fda-approves-takeda-s-sleep-disorder-pill-be4cb3a9110ed9d5Pharma Surgeen2026-08-05T22:48:03.000ZUS FDA approves Takeda's sleep disorder pillhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-08664695aaeafb3fPharma Surgeen2026-08-05T22:48:03.000ZTakeda Pharmaceutical Company Limitedhttps://www.pharmaradar360.com/article/the-logo-of-japanese-takeda-pharmaceutical-co-is-seen-at-an-office-building-in-g-96d3d088d849662cPharma Surgeen2026-08-05T22:47:49.000ZThe logo of Japanese Takeda Pharmaceutical Co is seen at an office building in Glattbrugghttps://www.pharmaradar360.com/article/maharashtra-food-and-drug-administration-places-one-year-ban-on-analogue-non-dai-abdb416185bd8230Pharma Surgeen2026-08-05T22:44:40.000ZMaharashtra Food and Drug Administration places one-year ban on analogue, non-dairy paneerhttps://www.pharmaradar360.com/article/fda-finalizes-antimicrobial-animal-drug-safety-guidance-c256962891a03a40Pharma Surgeen2026-08-05T22:13:52.000ZFDA finalizes antimicrobial animal drug safety guidancehttps://www.pharmaradar360.com/article/victory-medical-center-pharmacy-issues-voluntary-nationwide-recall-of-certain-lo-76991f9cf5f6d723Pharma Surgeen2026-08-05T22:06:22.000ZVictory Medical Center Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levelshttps://www.pharmaradar360.com/article/vir-biotech-earnings-beat-by-0-14-revenue-topped-estimates-deae90193e64929cPharma Surgeen2026-08-05T21:45:00.000ZVir Biotech earnings beat by $0.14, revenue topped estimateshttps://www.pharmaradar360.com/article/biotech-backed-psoriasis-skincare-d9963547d37bd9afPharma Surgeen2026-08-05T21:39:41.000ZBiotech-Backed Psoriasis Skincarehttps://www.pharmaradar360.com/article/top-portage-biotech-alp-competitors-2026-f77a722fc11c05f7Pharma Surgeen2026-08-05T21:36:25.000ZTop Portage Biotech (ALP) Competitors 2026https://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abbPharma Surgeen2026-08-05T21:30:02.000ZMajor expansion of community mental health support across Englandhttps://www.pharmaradar360.com/article/pharmaceutical-technology-launches-premium-subscription-service-for-industry-dat-a78dc29dd3e2ba00Pharma Surgeen2026-08-05T21:24:05.000ZPharmaceutical Technology Launches Premium Subscription Service for Industry Data and Analysishttps://www.pharmaradar360.com/article/biotech-ipo-fever-shows-no-signs-of-breaking-807c4e539d48cd54Pharma Surgeen2026-08-05T21:19:25.000ZBiotech IPO Fever Shows No Signs of Breakinghttps://www.pharmaradar360.com/article/applied-biologics-gains-irb-approval-for-phase-3-bioxheal-trial-in-diabetic-foot-a4970671f1d1be39Pharma Surgeen2026-08-05T21:15:33.000ZApplied Biologics Gains IRB Approval for Phase 3 BIOxHEAL Trial in Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/teaching-ai-to-know-all-about-drugs-not-just-their-shape-a-new-way-to-predict-dr-4dc00cb55ae4e823Pharma Surgeen2026-08-05T20:43:23.000ZTeaching AI to "Know" All About Drugs, Not Just Their Shape: A New Way to Predict Drug Toxicityhttps://www.pharmaradar360.com/article/manufacturing-deal-prepares-rett-gene-therapy-for-potential-u-s-launch-bfbaa7f1010cb639Pharma Surgeen2026-08-05T20:36:57.000ZManufacturing deal prepares Rett gene therapy for potential U.S. launchhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-innovation1-biotech-inc-otc-ivbt-66c38166940524c0Pharma Surgeen2026-08-05T20:27:13.000ZEnterprise value to EBITDA forward of Innovation1 Biotech Inc. – OTC:IVBThttps://www.pharmaradar360.com/article/who-is-steven-quay-the-biotech-exec-likely-to-take-fauci-s-old-job-e191144ef72f5307Pharma Surgeen2026-08-05T20:23:38.000ZWho Is Steven Quay, the Biotech Exec Likely to Take Fauci's Old Job?https://www.pharmaradar360.com/article/moleculin-biotech-inc-mbrx-cfo-buys-293-333-shares-and-879-999-warrants-e5f518d3466ec735Pharma Surgeen2026-08-05T20:17:50.000ZMoleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrantshttps://www.pharmaradar360.com/article/moleculin-biotech-mbrx-cso-buys-common-stock-and-series-i-warrants-5d0790f56fa83f91Pharma Surgeen2026-08-05T20:16:24.000ZMoleculin Biotech (MBRX) CSO buys common stock and Series I Warrantshttps://www.pharmaradar360.com/article/lotte-holdings-invests-in-metaphore-10th-hb-cvc-biotech-deal-b0d7cb63ce69a82aPharma Surgeen2026-08-05T20:07:35.000ZLotte Holdings invests in Metaphore, 10th HB-CVC biotech dealhttps://www.pharmaradar360.com/article/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-a-bus-03249f73f6acd4e0Pharma Surgeen2026-08-05T20:05:00.000ZEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Updatehttps://www.pharmaradar360.com/article/patients-with-motor-neurone-disease-set-for-fast-tracked-care-dc0c98a04db38079Pharma Surgeen2026-08-05T19:59:59.000ZPatients with motor neurone disease set for fast-tracked carehttps://www.pharmaradar360.com/article/amgen-details-phase-3-sleep-apnea-studies-for-investigational-drug-maritide-13ea84f69e00f7abPharma Surgeen2026-08-05T19:43:36.000ZAmgen Details Phase 3 Sleep Apnea Studies for Investigational Drug MariTidehttps://www.pharmaradar360.com/article/cleveland-startup-pitches-federal-biotech-commission-on-regenerative-medicine-hu-13279b8330e99f48Pharma Surgeen2026-08-05T19:43:00.000ZCleveland startup pitches federal biotech commission on regenerative medicine hubhttps://www.pharmaradar360.com/article/moderna-launches-early-trial-of-ebola-mrna-vaccine-d45ac1e3f0eab751Pharma Surgeen2026-08-05T19:34:10.000ZModerna launches early trial of Ebola mRNA vaccinehttps://www.pharmaradar360.com/article/fda-suspends-licenses-of-5-food-outlets-in-pune-div-19996c29b602ea6bPharma Surgeen2026-08-05T19:19:00.000ZFDA suspends licenses of 5 food outlets in Pune divhttps://www.pharmaradar360.com/article/krystal-biotech-krys-after-its-q2-beat-is-the-valuation-case-still-intact-482aed0d642dc06fPharma Surgeen2026-08-05T19:15:40.000ZKrystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intacthttps://www.pharmaradar360.com/article/biotech-security-a-new-national-defense-priority-ea275c7ca3479468Pharma Surgeen2026-08-05T19:12:39.000ZBiotech Security: A New National Defense Priorityhttps://www.pharmaradar360.com/article/source-denies-astrazeneca-bristol-myers-merger-talks-pharmexec-d0fbd53fd1496d33Pharma Surgeen2026-08-05T19:02:42.000ZSource Denies AstraZeneca-Bristol Myers Merger Talks | PharmExechttps://www.pharmaradar360.com/article/sanofi-suspends-chronic-lung-disease-phase-2-study-tied-to-strategic-business-re-c2570cc44cdf2ce0Pharma Surgeen2026-08-05T18:50:22.000ZSanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’https://www.pharmaradar360.com/article/4dmt-reports-new-phase-2b-gene-therapy-data-for-wet-amd-6a0c45854be523b9Pharma Surgeen2026-08-05T18:49:23.000Z4DMT reports new phase 2b gene therapy data for wet AMDhttps://www.pharmaradar360.com/article/government-did-not-conduct-impact-assessment-for-community-pharmacy-prescribing-0af693af00bbdefdPharma Surgeen2026-08-05T18:22:26.000ZGovernment did not conduct impact assessment for community pharmacy prescribinghttps://www.pharmaradar360.com/article/sellas-life-sciences-faces-earnings-test-as-trial-nears-end-026a83e5ad9651fcPharma Surgeen2026-08-05T17:55:00.000ZSellas Life Sciences faces earnings test as trial nears endhttps://www.pharmaradar360.com/article/compass-pathways-q2-2026-loss-widens-358-5-beyond-estimates-46627f0dc24cad8aPharma Surgeen2026-08-05T17:52:53.000ZCOMPASS Pathways Q2 2026 Loss Widens 358.5% Beyond Estimateshttps://www.pharmaradar360.com/article/decision-advertising-investigations-july-2026-76a504b6c1b42a35Pharma Surgeen2026-08-05T17:47:17.000ZDecision: Advertising investigations: July 2026https://www.pharmaradar360.com/article/abpi-response-to-the-budget-266d5a44ca7fed70Pharma Surgeen2026-08-05T17:40:47.000ZABPI response to the Budgethttps://www.pharmaradar360.com/article/uk-must-get-ready-for-new-cell-and-gene-therapies-says-abpi-7a9d4799206ea168Pharma Surgeen2026-08-05T17:36:31.000ZUK must get ready for new cell and gene therapies, says ABPIhttps://www.pharmaradar360.com/article/fresenius-kabi-issues-voluntary-nationwide-recall-of-one-lot-of-morphine-sulfate-145ab2d6d03d9806Pharma Surgeen2026-08-05T17:35:16.000ZFresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-uphttps://www.pharmaradar360.com/article/biontech-s-investment-provides-a-template-for-uk-growth-say-abpi-f1873a753ad33604Pharma Surgeen2026-08-05T17:32:05.000ZBioNTech’s investment provides a template for UK growth, say ABPIhttps://www.pharmaradar360.com/article/making-wales-a-destination-for-industry-clinical-trials-and-medical-research-eac003c6b3f5fe5cPharma Surgeen2026-08-05T17:30:13.000ZMaking Wales a destination for industry clinical trials and medical researchhttps://www.pharmaradar360.com/article/maharashtra-becomes-2nd-state-to-ban-analogue-cheese-violators-face-up-to-six-mo-fdcd35ec3c5116a4Pharma Surgeen2026-08-05T17:27:00.000ZMaharashtra becomes 2nd state to ban analogue cheese; violators face up to six months' jail, Rs 1 lakh finehttps://www.pharmaradar360.com/article/new-data-shows-uk-life-sciences-failing-to-reach-its-potential-0d950ee6c3e234bdPharma Surgeen2026-08-05T17:23:49.000ZNew data shows UK life sciences failing to reach its potentialhttps://www.pharmaradar360.com/article/psychedelic-drug-development-takes-center-stage-do-you-have-what-it-takes-to-bri-c0614053439a87d8Pharma Surgeen2026-08-05T17:07:01.000ZPsychedelic Drug Development Takes Center Stage – Do You Have What it Takes to Bring a Psychedelic Drug to Market?https://www.pharmaradar360.com/article/fda-s-2026-draft-guidance-on-nonclinical-safety-for-antibody-drug-conjugates-2eed62d188f90e94Pharma Surgeen2026-08-05T17:02:19.000ZFDA’s 2026 Draft Guidance on Nonclinical Safety for Antibody Drug Conjugateshttps://www.pharmaradar360.com/article/fda-guidance-clinical-pipelines-and-the-emerging-deal-landscape-of-psychedelic-t-6621f8aa43e5df7dPharma Surgeen2026-08-05T16:55:08.000ZFDA Guidance, Clinical Pipelines, and the Emerging Deal Landscape of Psychedelic Therapeuticshttps://www.pharmaradar360.com/article/biotech-company-expanding-to-gramercy-park-despite-industry-headwinds-3c43a5cef96e9e50Pharma Surgeen2026-08-05T16:55:00.000ZBiotech company expanding to Gramercy Park despite industry headwindshttps://www.pharmaradar360.com/article/belgian-company-selects-sa-for-us-headquarters-06c396ce17c234b8Pharma Surgeen2026-08-05T16:55:00.000ZBelgian company selects SA for US headquartershttps://www.pharmaradar360.com/article/america-s-next-biotech-challenge-f8140dbd48c77a56Pharma Surgeen2026-08-05T16:42:09.000ZAmerica’s Next Biotech Challengehttps://www.pharmaradar360.com/article/shionogi-advances-phase-3-secutrelvir-trial-eyeing-new-covid-19-market-upside-34fe502b3a64ab8ePharma Surgeen2026-08-05T16:40:33.000ZShionogi Advances Phase 3 Secutrelvir Trial, Eyeing New COVID-19 Market Upsidehttps://www.pharmaradar360.com/article/biotech-attovia-therapeutics-climbs-24-after-289-million-ipo-2c49662a21ea9706Pharma Surgeen2026-08-05T16:31:52.000ZBiotech Attovia Therapeutics Climbs 24% After $289 Million IPOhttps://www.pharmaradar360.com/article/this-is-nvidia-ceo-jensen-huang-s-favorite-biotech-stock-and-you-ve-probably-nev-58ccc039104312d1Pharma Surgeen2026-08-05T16:30:00.000ZThis Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of Ithttps://www.pharmaradar360.com/article/attovia-adds-to-biotech-ipo-momentum-with-289m-offering-4a4f6fff23306e69Pharma Surgeen2026-08-05T16:19:45.000ZAttovia adds to biotech IPO momentum with $289M offeringhttps://www.pharmaradar360.com/article/scottish-kidney-disease-biotech-mironid-raises-46-million-to-advance-rare-diseas-1b6d710b27244070Pharma Surgeen2026-08-05T16:12:39.000ZScottish kidney disease biotech Mironid raises $46 million to advance rare disease pipelinehttps://www.pharmaradar360.com/article/capra-biosciences-receives-additional-funding-for-domestic-pharmaceutical-api-bi-5b311269cba6bbeePharma Surgeen2026-08-05T16:11:22.000ZCapra Biosciences receives additional funding for domestic pharmaceutical API biomanufacturinghttps://www.pharmaradar360.com/article/the-commodification-of-legal-healing-psychedelics-29fdc15e58528b3bPharma Surgeen2026-08-05T15:54:14.000ZThe Commodification of Legal Healing Psychedelicshttps://www.pharmaradar360.com/article/lilly-climbs-novo-falls-as-obesity-drug-battle-intensifies-947c347b40352562Pharma Surgeen2026-08-05T15:40:26.000ZLilly climbs, Novo falls as obesity drug battle intensifieshttps://www.pharmaradar360.com/article/child-death-overview-panels-contacts-5f107f83b6a24c3fPharma Surgeen2026-08-05T15:37:33.000ZChild death overview panels: contactshttps://www.pharmaradar360.com/article/beyond-the-megamerger-how-rumored-astrazeneca-bms-discussions-signal-a-new-era-o-19699d10d2f03d7aPharma Surgeen2026-08-05T15:17:36.000ZBeyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competitionhttps://www.pharmaradar360.com/article/how-drone-delivery-is-moving-closer-to-pharma-s-last-mile-c0ae477b30f1ac1cPharma Surgeen2026-08-05T15:11:55.000ZHow Drone Delivery Is Moving Closer to Pharma's Last Milehttps://www.pharmaradar360.com/article/approach-online-weight-loss-drug-offers-with-skepticism-57e68aeb6e6a3ad7Pharma Surgeen2026-08-05T15:10:31.000ZApproach online weight-loss drug offers with skepticismhttps://www.pharmaradar360.com/article/medera-partners-with-iqvia-to-accelerate-cardiac-gene-therapies-and-human-based-864a3f11c3144c06Pharma Surgeen2026-08-05T15:07:31.000ZMedera Partners with IQVIA to Accelerate Cardiac Gene Therapies and Human-Based Drug Discovery Platformshttps://www.pharmaradar360.com/article/maharashtra-fda-seizes-rs-55-72-crore-worth-of-unsafe-food-suspends-165-licences-e93d6e92ecd369ecPharma Surgeen2026-08-05T15:02:00.000ZMaharashtra FDA seizes Rs 55.72 crore worth of unsafe food, suspends 165 licences in two-month crackdownhttps://www.pharmaradar360.com/article/medicine-supply-management-49792371bdddb531Pharma Surgeen2026-08-05T14:55:41.000ZMedicine supply managementhttps://www.pharmaradar360.com/article/ensuring-the-efficient-supply-and-distribution-of-medicines-to-patients-ad6631405329da7bPharma Surgeen2026-08-05T14:50:37.000ZEnsuring the efficient supply and distribution of medicines to patientshttps://www.pharmaradar360.com/article/long-term-real-world-safety-and-effectiveness-of-arimoclomol-in-individuals-with-137c3fc85c443747Pharma Surgeen2026-08-05T14:37:42.000ZLong-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Outcomes from the US early access program over a 4-year periodhttps://www.pharmaradar360.com/article/fda-continues-enforcement-drive-against-food-safety-violations-5434926939a4f813Pharma Surgeen2026-08-05T14:30:08.000ZFDA continues Enforcement Drive against Food Safety Violationshttps://www.pharmaradar360.com/article/collegium-pharmaceutical-earnings-ahead-after-adhd-acquisition-by-investing-com-7563c8042079448ePharma Surgeen2026-08-05T14:25:44.000ZCollegium Pharmaceutical earnings ahead after ADHD acquisition By Investing.comhttps://www.pharmaradar360.com/article/what-kenco-s-ai-rollout-signals-for-3pl-6ae1a4363d17b4c0Pharma Surgeen2026-08-05T14:21:55.000ZWhat Kenco's AI Rollout Signals for 3PLhttps://www.pharmaradar360.com/article/building-a-more-resilient-healthcare-future-insights-from-aspen-s-dr-stavros-nic-c504d93cd0680379Pharma Surgeen2026-08-05T14:17:04.000ZBuilding a More Resilient Healthcare Future: Insights from Aspen’s Dr Stavros Nicolaouhttps://www.pharmaradar360.com/article/america-s-next-biotech-challenge-7a519961de832d68Pharma Surgeen2026-08-05T14:06:59.000ZAmerica’s Next Biotech Challengehttps://www.pharmaradar360.com/article/cspc-pharmaceutical-astrazeneca-form-joint-venture-for-biologics-manufacturing-i-b4881cb4abb4ee03Pharma Surgeen2026-08-05T14:02:36.000ZCSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in Chinahttps://www.pharmaradar360.com/article/video-moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-to-help-fight-outbr-b233bcde0a650915Pharma Surgeen2026-08-05T14:02:18.000ZVideo Moderna begins Phase 1 clinical trial of Ebola vaccine to help fight outbreakhttps://www.pharmaradar360.com/article/investors-brace-for-vir-biotech-earnings-amid-turnaround-bid-by-investing-com-472a9b471e741d0ePharma Surgeen2026-08-05T13:56:48.000ZInvestors brace for Vir Biotech earnings amid turnaround bid By Investing.comhttps://www.pharmaradar360.com/article/novo-nordisk-stock-shock-has-investors-rethinking-obesity-drug-exposure-4f84f83916f6db31Pharma Surgeen2026-08-05T13:55:27.000ZNovo Nordisk Stock Shock Has Investors Rethinking Obesity Drug Exposurehttps://www.pharmaradar360.com/article/digital-inclusion-action-plan-one-year-on-1d3fd03658d0d477Pharma Surgeen2026-08-05T13:45:47.000ZDigital Inclusion Action Plan: One Year Onhttps://www.pharmaradar360.com/article/novartis-enrolled-first-participant-in-phase-3-preserve-clinical-trial-for-exper-d5f8cd2e0c0c6485Pharma Surgeen2026-08-05T13:00:45.000ZNovartis Enrolled First Participant in Phase 3 PRESERVE Clinical Trial for Experimental PSP-RS Treatmenthttps://www.pharmaradar360.com/article/north-carolina-pharmaceutical-company-laying-off-47-in-hoover-leaving-birmingham-3e3296c45085ecd6Pharma Surgeen2026-08-05T12:45:00.000ZNorth Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham areahttps://www.pharmaradar360.com/article/fda-approves-long-lasting-otc-pain-reliever-combining-acetaminophen-and-naproxen-b705877d8a45bc85Pharma Surgeen2026-08-05T12:43:01.000ZFDA approves long-lasting OTC pain reliever combining acetaminophen and naproxenhttps://www.pharmaradar360.com/article/new-nsf-initiative-drives-ai-enabled-scientific-discovery-172e309b199542cfPharma Surgeen2026-08-05T12:38:00.000ZNew NSF initiative drives AI-enabled scientific discoveryhttps://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-671bce17695a553aPharma Surgeen2026-08-05T12:32:17.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/alteogen-announces-exclusive-license-agreement-with-a-global-pharmaceutical-comp-767e313e97ed282dPharma Surgeen2026-08-05T12:30:49.000ZAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Producthttps://www.pharmaradar360.com/article/adneuris-therapeutics-grants-exclusive-license-to-maruishi-pharmaceutical-to-adv-9adfeb9c1c198156Pharma Surgeen2026-08-05T12:30:00.000ZAdneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Koreahttps://www.pharmaradar360.com/article/five-biospace-nextgen-companies-account-for-one-third-of-2026-biotech-ipos-e4719d9059366612Pharma Surgeen2026-08-05T12:18:30.000ZFive BioSpace NextGen Companies Account for One-Third of 2026 Biotech IPOshttps://www.pharmaradar360.com/article/health-canada-approves-moderna-phase-1-clinical-trials-for-mrna-ebola-vaccine-am-9f6251f536b7741dPharma Surgeen2026-08-05T12:08:36.000ZHealth Canada Approves Moderna Phase 1 Clinical Trials for mRNA Ebola Vaccine Amid DRC Outbreakhttps://www.pharmaradar360.com/article/sanofi-backed-expedition-uses-115m-series-b-to-advance-copd-drug-on-phase-2-jour-28b5c4bcb2b25a24Pharma Surgeen2026-08-05T12:02:58.000ZSanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journeyhttps://www.pharmaradar360.com/article/research-innovators-finding-a-cure-introduces-students-to-pharmaceutical-careers-6fc9cf15d7d8d59aPharma Surgeen2026-08-05T12:02:35.000ZResearch Innovators Finding a Cure introduces students to pharmaceutical careershttps://www.pharmaradar360.com/article/med-rx-wound-care-kits-718bd18a739705acPharma Surgeen2026-08-05T12:00:00.000ZMed-RX Wound Care Kitshttps://www.pharmaradar360.com/article/filmarray-ngds-warrior-panel-24e67aca8615b8d0Pharma Surgeen2026-08-05T12:00:00.000ZFilmArray® NGDS Warrior Panelhttps://www.pharmaradar360.com/article/1788-4k-camera-e6d94eaea5b17575Pharma Surgeen2026-08-05T12:00:00.000Z1788 4K Camerahttps://www.pharmaradar360.com/article/systimmune-announces-first-patient-dosed-in-global-phase-3-trial-of-bl-m14d1-in-61f74eb64819f62aPharma Surgeen2026-08-05T12:00:00.000ZSystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/expedition-gets-another-115m-for-its-twist-on-china-newco-model-35b44d19760c8482Pharma Surgeen2026-08-05T12:00:00.000ZExpedition gets another $115M for its twist on China NewCo modelhttps://www.pharmaradar360.com/article/what-is-premium-content-on-pharmaceutical-technology-3346b038dd63c932Pharma Surgeen2026-08-05T11:54:14.000ZWhat is ‘Premium Content’ on Pharmaceutical Technology?https://www.pharmaradar360.com/article/son-of-lukashenka-s-alleged-partner-to-build-10m-pharmaceutical-plant-in-belarus-42d2c12e1b963462Pharma Surgeen2026-08-05T11:44:00.000ZSon of Lukashenka’s alleged partner to build $10M pharmaceutical plant in Belarushttps://www.pharmaradar360.com/article/immuneering-reports-17-3-month-median-overall-survival-in-first-line-pancreatic-cb45b329b7c701cbPharma Surgeen2026-08-05T11:43:00.000ZImmuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trialhttps://www.pharmaradar360.com/article/kane-biotech-announces-engagement-of-dna-advisors-1f12fff0849db646Pharma Surgeen2026-08-05T11:38:19.000ZKane Biotech Announces Engagement of DNA Advisorshttps://www.pharmaradar360.com/article/charles-river-lifts-profit-forecast-on-improving-biotech-demand-c9fe8a74e8ea8d03Pharma Surgeen2026-08-05T11:34:59.000ZCharles River lifts profit forecast on improving biotech demandhttps://www.pharmaradar360.com/article/european-pharmacopoeia-opens-revised-monograph-macrogols-1444-for-consultation-57f3b969f8d63478Pharma Surgeen2026-08-05T11:29:26.000ZEuropean Pharmacopoeia opens revised monograph Macrogols (1444) for consultationhttps://www.pharmaradar360.com/article/kane-biotech-announces-engagement-of-dna-advisors-a23eee2cc4cefae5Pharma Surgeen2026-08-05T11:25:00.000ZKane Biotech Announces Engagement of DNA Advisorshttps://www.pharmaradar360.com/article/kane-reviews-options-wound-care-activity-began-in-u-s-and-canada-02f9b163c46aaf67Pharma Surgeen2026-08-05T11:25:00.000ZKane reviews options; wound-care activity began in U.S. and Canadahttps://www.pharmaradar360.com/article/applied-biologics-receives-central-irb-approval-for-phase-3-bioxhealtm-clinical-b54821630f8b4e95Pharma Surgeen2026-08-05T11:21:00.000ZApplied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trialhttps://www.pharmaradar360.com/article/eyepoint-reports-second-quarter-2026-financial-results-and-highlights-recent-cor-e79ed5ce65da96f9Pharma Surgeen2026-08-05T11:17:53.000ZEyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developmentshttps://www.pharmaradar360.com/article/la-aemps-informa-del-posible-fallo-en-un-componente-electrico-interno-de-determi-deea90efa7cc20d6Pharma Surgeen2026-08-05T11:16:16.000ZLa AEMPS informa del posible fallo en un componente eléctrico interno de determinados ventiladores Astral 100 y Astral 150https://www.pharmaradar360.com/article/mironid-banks-46m-in-series-b-to-take-rare-kidney-disease-drug-closer-to-clinic-ed5da85080c6b987Pharma Surgeen2026-08-05T11:02:58.000ZMironid banks $46m in Series B to take rare kidney disease drug closer to clinichttps://www.pharmaradar360.com/article/fur-real-biotech-startup-eliminates-major-dog-allergen-in-beagle-pups-using-cris-9e6f9ac5cf6633c2Pharma Surgeen2026-08-05T11:00:39.000ZFur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPRhttps://www.pharmaradar360.com/article/attovia-extends-biotech-ipo-streak-with-289m-listing-for-three-i-i-drugs-7b7fbc7139e99ac8Pharma Surgeen2026-08-05T11:00:00.000ZAttovia extends biotech IPO streak with $289M listing for three I&I drugshttps://www.pharmaradar360.com/article/attovia-s-ceo-aims-to-scratch-itch-opportunity-and-challenge-dupixent-with-289m-2d42d2c063a06174Pharma Surgeen2026-08-05T10:58:58.000ZAttovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOhttps://www.pharmaradar360.com/article/lilly-reports-second-quarter-2026-financial-results-raises-full-year-guidance-an-e28fa132935883a2Pharma Surgeen2026-08-05T10:45:00.000ZLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progresshttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-q2-loss-narrows-as-revenue-rises-2026-revenue-guidance-6cfae01a9d19e198Pharma Surgeen2026-08-05T10:38:03.000ZUltragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmedhttps://www.pharmaradar360.com/article/why-is-my-baby-being-offered-an-rsv-immunisation-7a9d75715e3cc53cPharma Surgeen2026-08-05T10:04:03.000ZWhy is my baby being offered an RSV immunisation?https://www.pharmaradar360.com/article/rockville-based-supernus-to-become-2-2-billion-pharmaceutical-company-through-me-7b25f31e71fb163bPharma Surgeen2026-08-05T10:00:08.000ZRockville-Based Supernus to Become $2.2 Billion Pharmaceutical Company Through Mergerhttps://www.pharmaradar360.com/article/gcc-expands-pharmaceutical-manufacturing-as-market-surpasses-30-billion-b0816bda893f2ba1Pharma Surgeen2026-08-05T09:58:35.000ZGCC expands pharmaceutical manufacturing as market surpasses $30 billionhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-purchased-by-royal-bank-of-canada-ed2bd672b94caea2Pharma Surgeen2026-08-05T09:54:02.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Royal Bank of Canadahttps://www.pharmaradar360.com/article/he-grew-up-near-boston-went-to-harvard-and-worked-at-mit-why-did-he-found-his-co-a5c0e4dda8298d9fPharma Surgeen2026-08-05T09:48:40.000ZHe grew up near Boston, went to Harvard, and worked at MIT. Why did he found his company in California?https://www.pharmaradar360.com/article/novo-nordisk-sues-eli-lilly-over-glp-1-advertising-expanding-scrutiny-of-drug-ma-cebc26e87e092246Pharma Surgeen2026-08-05T09:45:00.000ZNovo Nordisk sues Eli Lilly over GLP-1 advertising, expanding scrutiny of drug marketinghttps://www.pharmaradar360.com/article/zika-virus-sample-testing-advice-89184a09fce05a86Pharma Surgeen2026-08-05T09:38:55.000ZZika virus: sample testing advicehttps://www.pharmaradar360.com/article/this-company-should-be-in-massachusetts-bafcd7b9255cf680Pharma Surgeen2026-08-05T09:31:21.000ZThis company should be in Massachusettshttps://www.pharmaradar360.com/article/rovi-obtiene-la-medalla-gold-de-ecovadis-2026-y-mejora-su-puntuacion-global-hast-3e85a6406f058e6fPharma Surgeen2026-08-05T09:12:51.000ZROVI obtiene la medalla Gold de EcoVadis 2026 y mejora su puntuación global hasta los 83 puntoshttps://www.pharmaradar360.com/article/cryptosporidium-reference-unit-cru-e05d73b8212a95fcPharma Surgeen2026-08-05T09:07:05.000ZCryptosporidium Reference Unit (CRU)https://www.pharmaradar360.com/article/guidance-innovative-licensing-and-access-pathway-ilap-ec2fdf4140ef6775Pharma Surgeen2026-08-05T08:56:32.000ZGuidance: Innovative Licensing and Access Pathway (ILAP)https://www.pharmaradar360.com/article/takeda-pharmaceutical-seeks-india-s-backing-for-landmark-dengue-shot-43876e47bdef9e46Pharma Surgeen2026-08-05T08:53:11.000ZTakeda Pharmaceutical Seeks India's Backing for Landmark Dengue Shothttps://www.pharmaradar360.com/article/our-governance-e19412108cc777acPharma Surgeen2026-08-05T08:52:06.000ZOur governancehttps://www.pharmaradar360.com/article/pneumococcal-the-green-book-chapter-f14ee0573ebe09c4Pharma Surgeen2026-08-05T08:40:38.000ZPneumococcal: the green book chapterhttps://www.pharmaradar360.com/article/stronger-q2-results-guidance-hike-buybacks-might-change-the-case-for-investing-i-a99364df6d183fe7Pharma Surgeen2026-08-05T08:37:17.000ZStronger Q2 Results, Guidance Hike, Buybacks Might Change The Case For Investing In West (WST)https://www.pharmaradar360.com/article/cspc-pharmaceutical-and-astrazeneca-enter-jv-for-biologics-facility-in-china-68a5d3ab1d489d5cPharma Surgeen2026-08-05T08:32:47.000ZCSPC Pharmaceutical And AstraZeneca Enter JV For Biologics Facility In Chinahttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-monthly-data-2025-to-2026-46183ecdfec674ccPharma Surgeen2026-08-05T08:30:00.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026https://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-a79028947f82a41ePharma Surgeen2026-08-05T08:30:00.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-background-and-methodology-8c464f884dfbd989Pharma Surgeen2026-08-05T08:30:00.000ZMedicine supply disruption statistics, UK: background and methodologyhttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-1809a1bb48d946faPharma Surgeen2026-08-05T08:30:00.000ZMedicine supply disruption statistics, UKhttps://www.pharmaradar360.com/article/c-suite-changes-help-biotech-narrow-focus-but-maintain-drive-to-treat-fatal-neon-e425a5fd6796574dPharma Surgeen2026-08-05T08:03:10.000ZC-Suite Changes Help Biotech Narrow Focus But Maintain Drive To Treat Fatal Neonatal Brain Injuryhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-2-august-2026-9727509b061a9ef9Pharma Surgeen2026-08-05T08:00:17.000ZWeekly all-cause mortality surveillance: week ending 2 August 2026https://www.pharmaradar360.com/article/maharashtra-govt-bans-analogue-paneer-for-one-year-cites-food-safety-norm-violat-721ba054adf0af79Pharma Surgeen2026-08-05T07:43:03.000ZMaharashtra Govt Bans Analogue Paneer For One Year, Cites Food Safety Norm Violationshttps://www.pharmaradar360.com/article/litmus-changes-the-biopsy-calculus-what-the-nature-medicine-data-means-for-your-56106ecf83a9d08aPharma Surgeen2026-08-05T07:37:44.000ZLITMUS Changes the Biopsy Calculus: What the Nature Medicine Data Means for Your MASLD Protocolhttps://www.pharmaradar360.com/article/first-aid-biotech-act-divides-industry-patients-63292efba5ba981ePharma Surgeen2026-08-05T07:35:41.000ZFIRST AID: Biotech Act divides industry, patientshttps://www.pharmaradar360.com/article/from-licensing-deals-to-patients-ligachem-and-abl-bio-shift-focus-to-clinical-pr-5c15b1d86e415071Pharma Surgeen2026-08-05T07:12:03.000ZFrom licensing deals to patients: LigaChem and ABL Bio shift focus to clinical proofhttps://www.pharmaradar360.com/article/fda-portal-flooded-with-rivalry-driven-plaints-496ecf376d12b03ePharma Surgeen2026-08-05T07:08:09.000ZFDA portal flooded with rivalry-driven plaintshttps://www.pharmaradar360.com/article/from-molecule-to-medicine-the-process-behind-patient-ready-treatments-fe203f072693fe55Pharma Surgeen2026-08-05T07:00:00.000ZFrom molecule to medicine: the process behind patient-ready treatmentshttps://www.pharmaradar360.com/article/chinese-biotech-giant-wuxi-apptech-sees-h1-earnings-grow-1-3-e5857427affb307aPharma Surgeen2026-08-05T06:58:31.000ZChinese biotech giant WuXi AppTech sees H1 earnings grow 1/3https://www.pharmaradar360.com/article/why-china-s-biotech-rise-is-harder-to-contain-than-ai-4b6ef08548a33243Pharma Surgeen2026-08-05T06:53:54.000ZWhy China’s biotech rise is harder to contain than AIhttps://www.pharmaradar360.com/article/shy-therapeutics-doses-first-patient-in-shy-onc6-phase-1-trial-for-solid-tumors-2e3d6b5cf649f967Pharma Surgeen2026-08-05T06:48:36.000ZSHY Therapeutics Doses First Patient in SHY-ONC6 Phase 1 Trial for Solid Tumorshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-oxygenta-pharmaceutical-limited-bse-oxyge-04b1a5414726867bPharma Surgeen2026-08-05T06:41:44.000ZEnterprise value to revenue forward of Oxygenta Pharmaceutical Limited – BSE:OXYGENTAPHhttps://www.pharmaradar360.com/article/oric-launches-phase-3-trial-of-rinzimetostat-in-metastatic-prostate-cancer-d698ea9cb43392c6Pharma Surgeen2026-08-05T06:38:36.000ZORIC Launches Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancerhttps://www.pharmaradar360.com/article/q1-fy2026-financial-results-fa230a573f5915d5Pharma Surgeen2026-08-05T06:30:00.000ZQ1/FY2026 Financial resultshttps://www.pharmaradar360.com/article/lab-monkeys-for-26-000-show-china-s-biotech-quest-to-rival-us-23129f374f578896Pharma Surgeen2026-08-05T06:05:00.000ZLab Monkeys for $26,000 Show China’s Biotech Quest to Rival UShttps://www.pharmaradar360.com/article/la-aemps-informa-de-que-los-lotes-de-las-vacunas-veterinarias-monovalentes-frent-4e7733db4dc3f339Pharma Surgeen2026-08-05T06:00:41.000ZLa AEMPS informa de que los lotes de las vacunas veterinarias monovalentes frente a IBR, PIF y rabia requerirán de un certificado OBPR antes de su liberación y comercialización en Españahttps://www.pharmaradar360.com/article/asx-quarterly-health-wrap-regulatory-wins-clinical-progress-and-strategic-growth-b49063a198c2b227Pharma Surgeen2026-08-05T05:57:53.000ZASX Quarterly Health Wrap: Regulatory wins, clinical progress and strategic growthhttps://www.pharmaradar360.com/article/sterling-biotech-e2f02e10ec355aacPharma Surgeen2026-08-05T05:56:40.000ZSterling Biotechhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-cisen-pharmaceutical-ltd-class-a-sse-6033-658b8dc2e2a223e6Pharma Surgeen2026-08-05T05:04:44.000ZEnterprise value to revenue forward of Cisen Pharmaceutical Ltd. Class A – SSE:603367https://www.pharmaradar360.com/article/3d216ef31de7c8cdPharma Surgeen2026-08-05T05:03:12.000ZΑνάκληση της Άδειας Χονδρικής πώλησης φαρμάκων για Ανθρώπινη Χρήση στη φαρμακαποθήκη ΜΕΝΤΙΚΑΜΕΡΚ ΑΕhttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-08-05T04:48:07.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/cbd-gummies-safety-concerns-drug-interactions-2025-view-xxtwryucy-92683ddca5916e94Pharma Surgeen2026-08-05T04:31:08.000Zcbd gummies safety concerns drug interactions 2025 - View XxTWryucyhttps://www.pharmaradar360.com/article/4-potential-biotech-m-a-targets-plus-a-pretty-sure-bet-from-j-j-8a7357e0db65cbd0Pharma Surgeen2026-08-05T04:14:26.000Z4 potential biotech M&A targets, plus a pretty sure bet from J&Jhttps://www.pharmaradar360.com/article/novo-nordisk-shares-drop-after-drug-candidate-fails-in-trial-b758367c05ecb619Pharma Surgeen2026-08-05T04:00:50.000ZNovo Nordisk Shares Drop After Drug Candidate Fails in Trialhttps://www.pharmaradar360.com/article/fda-drug-approval-decisions-expected-in-september-2026-d37b4baa7f2f002aPharma Surgeen2026-08-05T04:00:00.000ZFDA Drug Approval Decisions Expected in September 2026https://www.pharmaradar360.com/article/3-biotech-stocks-with-massive-upside-to-buy-before-august-starts-c5467ef6dfd806f7Pharma Surgeen2026-08-05T03:53:36.000Z3 Biotech Stocks With Massive Upside to Buy Before August Startshttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-reports-earnings-tomorrow-what-to-expect-a03c473e79b7bf4cPharma Surgeen2026-08-05T03:36:00.000ZCollegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expecthttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-to-report-earnings-tomorrow-here-is-what-to-expect-98bd29becad5381fPharma Surgeen2026-08-05T03:34:18.000ZBioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expecthttps://www.pharmaradar360.com/article/shinsa-list-of-approved-regenerative-medical-products-april-2015-to-may-2026-13a81e82d9986c86Pharma Surgeen2026-08-05T03:00:00.000Z[SHINSA]List of Approved Regenerative Medical Products: April 2015 to May 2026https://www.pharmaradar360.com/article/onshoring-is-here-the-hiring-wave-is-still-a-decade-out-5296ecb39c08ed29Pharma Surgeen2026-08-05T02:52:14.000ZOnshoring Is Here. The Hiring Wave Is Still a Decade Outhttps://www.pharmaradar360.com/article/rohto-pharmaceutical-co-revenue-breakdown-otc-rphcf-1aa246098af6d55aPharma Surgeen2026-08-05T02:51:57.000ZRohto Pharmaceutical Co. Revenue Breakdown – OTC:RPHCFhttps://www.pharmaradar360.com/article/phase-3-korean-trial-backs-carboplatin-in-early-triple-negative-breast-cancer-39ef1905c63d2636Pharma Surgeen2026-08-05T02:43:46.000ZPhase 3 Korean trial backs carboplatin in early triple-negative breast cancerhttps://www.pharmaradar360.com/article/is-cbd-gummies-fda-approved-view-h2rzie3s8-470a235d153320dbPharma Surgeen2026-08-05T02:22:48.000Zis cbd gummies fda approved - View H2rZIE3s8https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-biotech-growth-trust-plc-lse-biog-57341996fdf8bde7Pharma Surgeen2026-08-05T02:12:08.000ZEnterprise value to EBIT forward of Biotech Growth Trust PLC – LSE:BIOGhttps://www.pharmaradar360.com/article/big-pharma-reshuffles-split-korea-biotech-as-assets-race-toward-trials-and-sales-d2e232d8e20f32e9Pharma Surgeen2026-08-05T02:10:00.000ZBig pharma reshuffles split Korea biotech as assets race toward trials and sales - CHOSUNBIZhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-ch-biotech-r-d-co-ltd-twse-6534-4a020f4d24657380Pharma Surgeen2026-08-05T02:07:42.000ZEnterprise value to EBITDA forward of CH Biotech R&D Co., Ltd. – TWSE:6534https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-q2-earnings-call-highlights-1df183332e9464caPharma Surgeen2026-08-05T02:03:00.000ZUltragenyx Pharmaceutical Q2 Earnings Call Highlightshttps://www.pharmaradar360.com/article/widened-access-to-diabetes-medicines-to-benefit-over-30-000-new-zealanders-8586aadb23c90779Pharma Surgeen2026-08-05T02:00:00.000ZWidened access to diabetes medicines to benefit over 30,000 New Zealandershttps://www.pharmaradar360.com/article/california-biotech-company-erectile-dysfunction-view-9xve7uzrx-403b6b29bdb1d649Pharma Surgeen2026-08-05T01:50:39.000ZCalifornia Biotech Company Erectile Dysfunction - View 9xVe7uZrXhttps://www.pharmaradar360.com/article/cbd-gummies-safety-who-should-avoid-interactions-view-lbc1j3ccr-656127e539d84134Pharma Surgeen2026-08-05T01:49:25.000ZCBD Gummies Safety: Who Should Avoid Interactions - View lbc1J3CCrhttps://www.pharmaradar360.com/article/taiwan-launches-nt-10b-fund-to-back-biotech-commercialization-2168afe35652086ePharma Surgeen2026-08-05T01:45:00.000ZTaiwan launches NT$10B fund to back biotech commercializationhttps://www.pharmaradar360.com/article/goldman-backed-biotech-attovia-raises-289-million-in-us-ipo-07b7164ef9075fd3Pharma Surgeen2026-08-05T01:44:01.000ZGoldman-Backed Biotech Attovia Raises $289 Million in US IPOhttps://www.pharmaradar360.com/article/who-is-eligible-to-get-eli-lilly-s-experimental-weight-loss-drug-before-approval-596b25472cdf0fe2Pharma Surgeen2026-08-05T01:30:00.000ZWho Is Eligible To Get Eli Lilly's Experimental Weight Loss Drug Before Approval? Criteria Explainedhttps://www.pharmaradar360.com/article/geno-pharmatech-showcases-comprehensive-pharmaceutical-facility-solutions-for-bi-fbe3f1c9450ddcb6Pharma Surgeen2026-08-05T01:05:00.000ZGENO Pharmatech Showcases Comprehensive Pharmaceutical Facility Solutions for Biotech Buyers Seeking GMP Cleanroom Construction and Turnkey Cleanroom EPC Expertisehttps://www.pharmaradar360.com/article/exilby-fda-fast-tracks-cannabis-derived-painkiller-disrupting-multi-billion-doll-5d5d3bb3171b1501Pharma Surgeen2026-08-05T00:38:32.000ZExilby: FDA Fast-Tracks Cannabis-Derived Painkiller Disrupting Multi-Billion-Dollar Opioid Industryhttps://www.pharmaradar360.com/article/cbd-gummies-safety-who-should-avoid-them-according-to-fda-stance-view-bzizhv2ya-5af4f39494df27c4Pharma Surgeen2026-08-05T00:28:21.000ZCBD Gummies Safety: Who Should Avoid Them According to FDA Stance - View bzizhV2yahttps://www.pharmaradar360.com/article/cbd-gummies-fda-regulation-safety-third-party-testing-view-h07c7bpku-91fe4e27718a2301Pharma Surgeen2026-08-05T00:20:59.000Zcbd gummies fda regulation safety third-party testing - View H07C7BpKuhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-08-05T00:19:10.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/is-cbd-gummies-considered-a-drug-view-kwabtzfcj-fcb9ded3ff69e124Pharma Surgeen2026-08-05T00:02:14.000ZIs CBD Gummies Considered a Drug - View kwABtZfcJhttps://www.pharmaradar360.com/article/eli-lilly-filed-form-10-q-d11c73569e2d32faPharma Surgeen2026-08-05T00:00:00.000ZEli Lilly filed Form 10-Qhttps://www.pharmaradar360.com/article/eli-lilly-filed-form-8-k-6399e210c7d422cbPharma Surgeen2026-08-05T00:00:00.000ZEli Lilly filed Form 8-Khttps://www.pharmaradar360.com/article/amgen-filed-form-10-q-b55e3dbf47bbc6a9Pharma Surgeen2026-08-05T00:00:00.000ZAmgen filed Form 10-Qhttps://www.pharmaradar360.com/article/abbvie-filed-form-8-k-08b18a8b4125bfc8Pharma Surgeen2026-08-05T00:00:00.000ZAbbVie filed Form 8-Khttps://www.pharmaradar360.com/article/08-05-2026-press-release-ir-news-santen-joins-inaugural-global-summit-for-eye-he-9b6412eeab8ac791Pharma Surgeen2026-08-05T00:00:00.000Z08.05.2026 Press Release IR News Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partnerhttps://www.pharmaradar360.com/article/micro-tracers-inc-response-to-objections-and-requests-for-a-public-hearing-c305e48be3e49778Pharma Surgeen2026-08-05T00:00:00.000ZMicro-Tracers, Inc.; Response to Objections and Requests for a Public Hearinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-11aa746e7211d87ePharma Surgeen2026-08-05T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetings